{
    "clinical_study": {
        "@rank": "25119", 
        "arm_group": {
            "arm_group_label": "SM-13496  20-120mg", 
            "arm_group_type": "Experimental", 
            "description": "once daily orally"
        }, 
        "brief_summary": {
            "textblock": "The study evaluates the long-term efficacy and safety of SM-13496 in patients with bipolar I\n      disorder."
        }, 
        "brief_title": "A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Bipolar I Disorder", 
        "detailed_description": {
            "textblock": "The study objective is to evaluate the long-term efficacy and safety of SM-13496 (20-120\n      mg/day) in patients with bipolar I disorder."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients who completed the D1002001 study\n\n        \u30fbPatients who completed the D1002001 study and who are considered by the investigator to\n        be eligible and without safety concerns.\n\n        Patients who did not participate in the D1002001 study\n\n          -  Patients who were fully informed of and understand the objectives, procedures, and\n             possible benefits and risks of the study and who provided written voluntary consent\n             to participate in the study.\n\n          -  Outpatients aged 18 through 74 years at the time of consent\n\n          -  Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode manic,\n             hypomanic, or mixed (\u2265 4 weeks and less than 12 months) without psychotic features.\n\n        Exclusion Criteria:\n\n          -  Patients with imminent risk of suicide or injury to self, others, or property.\n\n          -  Patients who are otherwise considered ineligible for the study by the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "405", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986114", 
            "org_study_id": "D1002002"
        }, 
        "intervention": {
            "arm_group_label": "SM-13496  20-120mg", 
            "description": "SM-13496 20-120mg", 
            "intervention_name": "SM-13496 (lurasidone HCl)", 
            "intervention_type": "Drug", 
            "other_name": "Lurasidone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 1, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Principal investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "China 5 sites"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Principal investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "Japan 60 sites"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Principal Investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Kuala Lumpur", 
                        "country": "Malaysia"
                    }, 
                    "name": "Malaysia 4 sites"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Principal Investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Manila", 
                        "country": "Philippines"
                    }, 
                    "name": "Philippines 5 sites"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Principal investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Russia 7 sites"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Principal investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "Taiwan 4 sites"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Principal Investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Kiev", 
                        "country": "Ukraine"
                    }, 
                    "name": "Ukraine 7 sites"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Japan", 
                "Malaysia", 
                "Philippines", 
                "Russian Federation", 
                "Taiwan", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.", 
        "overall_contact": {
            "email": "cc@ds-pharma.co.jp", 
            "last_name": "Dainippon Sumitomo Pharma Co., Ltd."
        }, 
        "overall_official": {
            "affiliation": "Dainippon Sumitomo Pharma", 
            "last_name": "Director, Drug Development Division", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events (AEs) and adverse drug reactions (ADRs)", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986114"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 52 weeks and each month"
            }, 
            {
                "measure": "Change from baseline in the Young Mania Rating Scale (YMRS) total score.", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 52 weeks and each month"
            }, 
            {
                "measure": "The time to recurrence/relapse of any mood event from clinical stability of bipolar disorder.", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "Dainippon Sumitomo Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dainippon Sumitomo Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}